Risk of ALT flare in patients with previous hepatitis B virus exposure on biological modifier therapies - a population-based study.

Jacky Chiu Leung HoJoyce Wing Yan MakTerry Cheuk Fung YipHong Man LamTsz Yan ChengTsz On LamLai Shan TamMan Fai LawCarmen Ka Man CheungSiew Chien NgVincent Wai Sun WongGrace Lai Hung Wong

Published in: Liver international : official journal of the International Association for the Study of the Liver (2022)

Our study further supports the current suggestion of prophylactic antiviral before starting anti-CD20 in HBV-exposed patients. While other biological therapies appear to have a lower risk for ALT flare, this result needs further confirmation.

Keyphrases

hepatitis b virus
end stage renal disease
liver failure
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported